Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BCAB

BioAtla Inc

Dec 07 • 04:00PM ET

1.55

Dollar change +0.15
Percentage change 10.71	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.65	Insider Own	24.43%	Shs Outstand	46.34M	Perf Week	-12.43%
Market Cap	74.09M	Forward P/E	-	EPS next Y	-2.55	Insider Trans	0.02%	Shs Float	36.13M	Perf Month	-11.93%
Income	-124.08M	PEG	-	EPS next Q	-0.79	Inst Own	58.23%	Short Float / Ratio	11.41% / 10.27	Perf Quarter	-35.15%
Sales	0.00M	P/S	-	EPS this Y	-0.82%	Inst Trans	11.61%	Short Interest	4.12M	Perf Half Y	-58.11%
Book/sh	1.98	P/B	0.78	EPS next Y	7.81%	ROA	-72.89%	Target Price	11.67	Perf Year	-84.30%
Cash/sh	2.96	P/C	0.52	EPS next 5Y	-	ROE	-104.56%	52W Range	1.24 - 10.38	Perf YTD	-81.21%
Dividend	-	P/FCF	-	EPS past 5Y	-34.47%	ROI	-129.31%	52W High	-85.06%	Beta	0.69
Dividend %	-	Quick Ratio	4.14	Sales past 5Y	-71.14%	Gross Margin	-	52W Low	25.00%	ATR	0.17
Employees	66	Current Ratio	4.14	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	48.59	Volatility	14.28% 11.01%
Optionable	Yes	Debt/Eq	0.03	EPS Q/Q	-1.40%	Profit Margin	-	Rel Volume	1.28	Prev Close	1.40
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 07 AMC	Payout	-	Avg Volume	401.59K	Price	1.55
Recom	1.00	SMA20	-0.90%	SMA50	-3.73%	SMA200	-40.90%	Volume	515,087	Change	10.71%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-22	Initiated	JMP Securities	Mkt Outperform	$17
May-05-22	Downgrade	Credit Suisse	Outperform → Neutral	$35 → $5
Mar-21-22	Initiated	H.C. Wainwright	Buy	$25
Oct-15-21	Resumed	BTIG Research	Buy	$68
Jun-28-21	Initiated	ROTH Capital	Buy	$75
May-05-21	Resumed	Credit Suisse	Outperform	$68
Apr-26-21	Resumed	Credit Suisse	Outperform	$68
Jan-11-21	Initiated	JP Morgan	Overweight	$45
Jan-11-21	Initiated	Jefferies	Buy	$51
Jan-11-21	Initiated	Credit Suisse	Outperform	$49
Jan-11-21	Initiated	BTIG Research	Buy	$47

Show Previous Ratings

Dec-06-23 08:00AM	BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 (GlobeNewswire)
Dec-05-23 08:00AM	BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event (GlobeNewswire)
Nov-30-23 08:00AM	BioAtla to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:00AM	BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC (GlobeNewswire) +8.16%
Nov-12-23 09:24AM	BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
04:01PM	Loading…
Nov-07-23 04:01PM	BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Nov-06-23 04:05PM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-12-23 07:30AM	BioAtla's Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award (GlobeNewswire) -5.46%
Oct-10-23 07:30AM	BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023 (GlobeNewswire) +15.12%
Sep-06-23 08:00AM	BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:01PM	BioAtla to Participate in Upcoming Investor Conferences in August (GlobeNewswire)
06:48AM	BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-02-23 11:31AM	Q2 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-23 04:01PM	BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Jul-25-23 08:00AM	BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023 (GlobeNewswire)
07:09AM	Loading…
Jul-07-23 07:09AM	With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners (Simply Wall St.)
Jun-26-23 08:00AM	BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index (GlobeNewswire) -9.43%
May-31-23 08:00AM	BioAtla to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
May-08-23 04:05PM	BioAtla to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire) -9.44%
May-04-23 08:00AM	BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 (GlobeNewswire)
Apr-29-23 09:29AM	We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +8.94%
Mar-27-23 07:12AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.51%
Mar-24-23 11:31AM	Q4 2022 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-23-23 04:05PM	BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-16-23 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights (GlobeNewswire)
Feb-27-23 08:07AM	BioAtla Announces Change in Executive Leadership (GlobeNewswire)
Feb-23-23 08:00AM	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma (GlobeNewswire) -8.83%
Jan-25-23 07:10AM	Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past year (Simply Wall St.) -5.39%
08:00AM	Loading…
Jan-10-23 08:00AM	BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones (GlobeNewswire) -46.24%
Dec-29-22 04:05PM	Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors (PR Newswire)
Dec-22-22 08:00AM	BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 08:54AM	BioAtla, Inc.'s stock is down 11%, but insiders still have about US$393k in profit after buying earlier this year (Simply Wall St.)
Dec-01-22 09:55AM	Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect? (Zacks)
Nov-15-22 09:55AM	Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect? (Zacks) -7.47%
Nov-11-22 08:38AM	Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth (Simply Wall St.) +10.32%
Nov-08-22 08:00AM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-22 11:15AM	BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +18.71%
09:08AM	BioAtla Announces $65 Million Underwritten Offering of its Common Stock (GlobeNewswire)
Nov-03-22 04:01PM	BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Oct-27-22 08:00AM	BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 (GlobeNewswire)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey) -5.76%
Sep-21-22 10:14AM	J.P. Morgan Says Stock Market Downside Risk Is Limited; Here Are 3 Stocks to Consider (TipRanks)
Sep-12-22 10:08AM	Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) (PR Newswire) -7.12%
Aug-18-22 06:39AM	Do Insiders Own Lots Of Shares In BioAtla, Inc. (NASDAQ:BCAB)? (Simply Wall St.)
Aug-09-22 07:25PM	BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress (GlobeNewswire)
Aug-03-22 08:00AM	BioAtla to Participate in the 2022 BTIG Biotechnology Conference (GlobeNewswire) +5.81%
Aug-02-22 08:00AM	BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022 (GlobeNewswire) +5.20%
Jun-04-22 08:12AM	Here's Why We're Watching BioAtla's (NASDAQ:BCAB) Cash Burn Situation (Simply Wall St.)
Jun-01-22 04:05PM	BioAtla to Participate in 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-04-22 04:01PM	BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire) +6.53%
Apr-08-22 08:00AM	BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022 (GlobeNewswire)
Mar-01-22 06:00AM	BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS (PR Newswire)
Feb-07-22 05:38PM	Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ... (GuruFocus.com)
Jan-10-22 04:05PM	BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors (PR Newswire)
Dec-21-21 09:00AM	BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS (PR Newswire)
Dec-11-21 06:34AM	Here's Why We're Not Too Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation (Simply Wall St.)
Nov-15-21 05:09PM	BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update (PR Newswire)
Oct-04-21 10:56AM	BioAtla, Inc. (BCAB) Fell Out Of Favor With Hedge Funds (Insider Monkey)
Sep-29-21 08:03AM	BioAtla Announces Private Placement of 2.7 Million Shares (PR Newswire)
Sep-12-21 08:49AM	What Kind Of Shareholders Hold The Majority In BioAtla, Inc.'s (NASDAQ:BCAB) Shares? (Simply Wall St.)
Aug-13-21 05:54PM	BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update (PR Newswire)
Jun-14-21 02:03AM	We're Hopeful That BioAtla (NASDAQ:BCAB) Will Use Its Cash Wisely (Simply Wall St.) -19.76%
May-12-21 06:26PM	BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update (PR Newswire)
Mar-16-21 01:59AM	Who Has Been Buying BioAtla, Inc. (NASDAQ:BCAB) Shares? (Simply Wall St.)
Dec-18-20 04:00PM	BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Dec-16-20 05:34PM	IPO of AI-Lending Firm Upstart Gains 47% (Barrons.com)
04:52PM	BioAtla Is the Latest Biotech IPO to Pop (Barrons.com)
Dec-15-20 07:59PM	BioAtla Announces Pricing of Initial Public Offering (PR Newswire)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCBRINN SYLVIA	Director	Sep 08	Buy	2.54	2,000	5,080	11,125	Sep 13 06:55 PM
SHORT JAY M PHD	Chief Executive Officer	Mar 29	Buy	2.47	40,800	100,862	1,412,387	Mar 30 07:17 PM
Vasquez Christian	See Remarks	Mar 28	Buy	2.40	20,000	47,970	102,709	Mar 29 05:20 PM
MCBRINN SYLVIA	Director	Dec 19	Buy	8.33	3,700	30,813	9,125	Dec 19 05:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAB

BioAtla Inc

Upgrade your FINVIZ experience